RecruitingNot applicableNCT06654752
Streamlined Treatment of Pulmonary Exacerbations in Pediatrics
Studying Cystic fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Washington, the Collaborative Health Studies Coordinating Center
- Principal Investigator
- D. B. Sanders, MD, MSIndiana University
- Intervention
- Immediate Oral Antibiotics(other)
- Enrollment
- 430 enrolled
- Eligibility
- 3-18 years · All sexes
- Timeline
- 2024 – 2029
Study locations (30)
- The Children's Hospital Alabama & University of Alabama at Birmingham, Birmingham, Alabama, United States
- Tucson Cystic Fibrosis Center, Tucson, Arizona, United States
- Children's Hospital of Los Angeles & Anton Yelchin Cystic Fibrosis Clinic, Los Angeles, California, United States
- Stanford University, Palo Alto, California, United States
- Rady Children's Hospital at University of California San Diego, San Diego, California, United States
- Children's Hospital of Colorado, Aurora, Colorado, United States
- Children's Healthcare of Atlanta & Emory University, Atlanta, Georgia, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago & Northwestern University, Chicago, Illinois, United States
- Riley Hospital for Children & Indiana University, Indianapolis, Indiana, United States
- University of Iowa, Iowa City, Iowa, United States
- Johns Hopkins Hospital, Johns Hopkins University, Baltimore, Maryland, United States
- Boston Children's Hospital & Harvard University, Boston, Massachusetts, United States
- University of Michigan Health System, Ann Arbor, Michigan, United States
- Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States
- The Minnesota Cystic Fibrosis Center & University of Minnesota, Minneapolis, Minnesota, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Cystic Fibrosis Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06654752 on ClinicalTrials.govOther trials for Cystic fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07437105Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNANCT07436351ACT With CF Self-Help ToolkitThomas Jefferson University
- RECRUITINGNANCT07314229Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-IvacaftorUniversity Hospital, Lille
- RECRUITINGNCT07083557Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)Bettina Mittendorfer
- RECRUITINGNCT07369414Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at HomeResearch Center Borstel
- RECRUITINGNCT07505797ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)iSono Health, Inc.
- RECRUITINGPHASE1NCT07283770Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNCT07363304Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.Meyer Children's Hospital IRCCS